Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenebrutinib Phase II in Active Rheumatoid Arthritis (ANDES)
NCT02833350Phase 2Completed
- Sponsor
- Genentech
- Start
- Sep 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of fenebrutinib in rheumatoid arthritis (RA) (7 cohorts), sponsored by Genentech. Primary endpoints: American College of Rheumatology 50% Response at Day 84 and Incidence of Adverse Events. Started Sep 2016; status: completed.
02
Drugs
fenebrutinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02833350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02833350.